Mesenchymal stromal cells alone or expressing interferon-β suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment

Kidd, Shannon; Caldwell, Lisa; Dietrich, Martin; Samudio, Ismael; Spaeth, Erika L.; Watson, Keri; Shi, Yuexi; Abbruzzese, James L.; Konopleva, Marina; Andreeff, Michael; Marini, Frank C.

doi:10.3109/14653241003631815

Cited by 168 publications

(130 citation statements)

References 48 publications

Supporting

Mentioning

122

Contrasting

Unclassified

Order By: Relevance

“…7 Tumor-directed migration and incorporation of MSCs have been demonstrated in a number of preclinical studies in vitro using transwell migration assays, and in vivo using animal tumor models. The homing capacity of MSCs has been demonstrated with almost all tested human cancer cell lines, including lung cancer, 8 malignant gliomas, 9--11 Kaposi's sarcomas, 12 breast cancer, 13,14 colon carcinoma, 15 pancreatic cancer, 16,17 melanoma 18 and ovarian cancer. 13 Engineered with tumor-specific anticancer genes, MSCs are capable of producing anticancer agents locally and constantly at the tumor site.…”

Section: Introductionmentioning

confidence: 99%

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

Sun

Rayat

et al. 2012

Cancer Gene Ther

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have attracted great interest in cancer therapy owing to their tumor-oriented homing capacity and the feasibility of autologous transplantation. Currently, pancreatic cancer patients face a very poor prognosis, primarily due to the lack of therapeutic strategies with an effective degree of specificity. Anticancer gene-engineered MSCs specifically target tumor sites and can produce anticancer agents locally and constantly. This study was performed to characterize pancreasderived MSCs and investigate the effects of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-engineered MSCs on pancreatic cancer cells under different culture conditions. Pancreas-derived MSCs exhibited positive expression on CD44, CD73, CD95, CD105, negative on CD34 and differentiated into adipogenic and osteogenic cells. TRAIL expression was assessed by both enzyme-linked immunosorbent assay and western blot analysis. Different patterns of TRAIL receptor expression were observed on the pancreatic cancer cell lines, including PANC1, HP62, ASPC1, TRM6 and BXPC3. Cell viability was assessed using a real-time monitoring system. Pancreatic cancer cell death was proportionally related to conditioned media from MSC nsTRAIL and MSC stTRAIL . The results suggest that MSCs exhibit intrinsic inhibition of pancreatic cancer cells and that this effect can be potentiated by TRAIL-transfection on death receptor-bearing cell types.

show abstract

Section: Introductionmentioning

confidence: 99%

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

Sun

Rayat

et al. 2012

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…Mesenchymal stromal cells are useful in delivering therapeutic protein to specific tissues as they can migrate to tumor or injury sites (Khakoo et al 2006;Kidd et al 2010;Pittenger and Martin 2004;Tomita et al 2002;Yen and Yen 2008). This offers an alternative treatment in lieu of recombinant protein therapy, as it reduces the cost of treatment, development of auto-antibody, and risks related to high concentration of recombinant proteins in the blood stream (Bennett et al 2004).…”

Section: Discussionmentioning

confidence: 99%

Extended and stable gene expression via nucleofection of MIDGE construct into adult human marrow mesenchymal stromal cells

et al. 2011

View full text Add to dashboard Cite

Human mesenchymal stromal cell (hMSC) is a potential target for cell and gene therapy-based approaches against a variety of different diseases. Whilst cationic lipofection has been widely experimented, the Nucleofector technology is a relatively new non-viral transfection method designed for primary cells and hard-to-transfect cell lines. Herein, we compared the efficiency and viability of nucleofection with cationic lipofection, and used the more efficient transfection method, nucleofection, to deliver a construct of minimalistic, immunologically defined gene expression encoding the erythropoietin (MIDGE-EPO) into hMSC. MIDGE construct is relatively safer than the viral and plasmid expression systems as the detrimental eukaryotic and prokaryotic gene and sequences have been eliminated. Using a plasmid encoding the luciferase gene, we demonstrated a high transfection efficiency using the U-23 (21.79 ± 1.09%) and C-17 (5.62 ± 1.09%) pulsing program in nucleofection. The cell viabilities were (44.93 ± 10.10)% and (21.93 ± 5.72)%, respectively 24 h post-nucleofection. On the other hand, lipofection treatment only yielded less than 0.6% efficiencies despite showing higher viabilities. Nucleofection did not affect hMSC renewability, immunophenotype and differentiation potentials. Subsequently, we nucleofected MIDGE-EPO using the U-23 pulsing program into hMSC. The results showed that, despite a low nucleofection efficiency with this construct, the EPO protein was stably expressed in the nucleofected cells up to 55 days when determined by ELISA or immunocytochemical staining. In conclusion, nucleofection is an efficient non-viral transfection approach for hMSC, which when used in conjunction with a MIDGE construct, could result in extended and stable transgene expression in hMSC.

show abstract

“…MSCs can efficiently produce biological products at the tumor sites and in a number of tumor models, MSCs expressing IFNβ have been shown to result in decreased tumor burden and increased animal survival [50]. A study has engineered MSCs to express TNF related apoptosis-inducing ligand (TRAIL) which causes apoptosis and death of cancer cells without harming normal cells by binding to specific TRAIL receptors and leading to activation of the extrinsic apoptosis pathway [51].…”

Section: Stem Cells As Delivery Vehicles In Gene Therapymentioning

confidence: 99%

Review on Stem Cell Therapy and their Role in Cancer Treatment

Mitku¹,

Tesfaye²,

Wubshet³

2017

IJBB

View full text Add to dashboard Cite

Mesenchymal stromal cells alone or expressing interferon-β suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment

Cited by 168 publications

References 48 publications

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cells

Extended and stable gene expression via nucleofection of MIDGE construct into adult human marrow mesenchymal stromal cells

Review on Stem Cell Therapy and their Role in Cancer Treatment

Contact Info

Product

Resources

About